Keyword: Sun Pharmaceutical
FDA clears Sun Pharma's key Halol plant, Eisai builds a new drug discovery center for Alzheimer's, opposition to the Takeda-Shire deal gains support.
After more than two years of intense effort, Sun Pharma has returned its key plant to the good graces of the FDA.
Takeda investors voice concerns over Shire deal; WuXi AppTec becomes the largest-cap CRO; two families' wealth swells on Gardasil nods.
The chairman of Zhifei Biological Products, which holds Chinese rights to Gardasil and Gardasil 9, boasted a net worth of about $4.6 billion Wednesday.
Sun Pharma, India's largest drug manufacturer, said pricing pressure in its generics market targeting the U.S. may lead to lower 2019 revenues.
Astellas plots 600 job cuts in Japan; GSK's infectious disease lead launches a Chinese biotech; Sun Pharma's Zytiga rival wins the FDA's blessing.
J&J says Zytiga won't face generics this year, but Sun just won FDA approval for its branded copy, a tweak on the big seller's active ingredient.
6 Dimensions makes a slew of biotech investments; Sun Pharma wins FDA nod for Ilumya; China plans 'zero tariff' policy on cancer drugs.
Sun Pharma’s $80 million psoriasis licensing deal just paid off. But now, its new drug Ilumya will go up against established player J&J.
Shionogi’s flu drug won Japanese approval; Sun Pharma's Halol plant was cited by the FDA; EpimAb hired a top Novartis researcher as CMO; plus more.